Utah Medical Products, Inc.
UTMD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.40 | 0.00 | 2.19 | -1.14 |
| FCF Yield | 0.00% | 1.50% | 2.31% | 1.41% |
| EV / EBITDA | 51.37 | 23.24 | 24.46 | 31.52 |
| Quality | ||||
| ROIC | 1.75% | 2.14% | 2.10% | 1.98% |
| Gross Margin | 51.57% | 50.80% | 57.03% | 58.12% |
| Cash Conversion Ratio | 0.94 | 1.47 | 1.01 | 1.08 |
| Growth | ||||
| Revenue 3-Year CAGR | -9.12% | -9.23% | -9.21% | -7.85% |
| Free Cash Flow Growth | 0.00% | -34.07% | 46.17% | -26.67% |
| Safety | ||||
| Net Debt / EBITDA | 0.06 | -17.88 | -19.83 | -20.76 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.59 | 0.59 | 0.48 | 0.44 |
| Cash Conversion Cycle | 173.37 | 170.61 | 203.40 | 230.70 |